Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

21 May 2023: Clinical Research  

Value of IL-1β and IL-23 in Predicting 28-Day Mortality Due to Sepsis: A Retrospective Study

Jing Cao1ABE*, Wenguang Liu1CDE, Yong Li1ABF, Bin Chen1CDE, Tingfeng Yu1DEF, Zhengbing He1BCD, Yanke Hong1EF

DOI: 10.12659/MSM.940163

Med Sci Monit 2023; 29:e940163



BACKGROUND: This research aimed to explore the utility of Interleukin-1β (IL-1β) and IL-23 as potential biomarkers for the diagnosis and prognosis of sepsis.

MATERIAL AND METHODS: This study included 74 adult individuals with sepsis, 45 ICU controls, and 50 healthy individuals attending routine physical examinations. IL-1β and IL-23 levels were assessed and analyzed on the admission day. Univariate Cox regression analyses were utilized to explore the association of IL-1β and IL-23 with sepsis survival. Furthermore, receiver operating characteristic (ROC) analysis was employed to evaluate the value of IL-1β and IL-23 to predict 28-day mortality due to sepsis.

RESULTS: Serum concentrations of IL-1β and IL-23 were significantly higher in septic patients relative to healthy and ICU controls (P<0.001). IL-1β and IL-23 levels in non-survivors were significantly higher than in survivors (P<0.001). IL-1β (hazard ratio; HR=1.06, P<0.001) and IL-23 (HR=1.02, P=0.031) were independent risk variables for 28-day mortality in sepsis patients, which were strongly associated with the severity of sepsis. The area under the ROC curve for predicting 28-day fatality in sepsis was 0.66 for IL-1β (P=0.024, 95% confidence interval; CI: 0.54-0.76) and 0.77 for IL-23 (P<0.001, 95% CI: 0.65-0.86). Furthermore, compared with low serum IL-1β (<9.41 pg/mL) and IL-23 (<6.77 pg/mL) levels, septic patients with high serum IL-1β (≥9.41 pg/mL) and IL-23 (≥6.77 pg/mL) levels had poorer survival.

CONCLUSIONS: Serum IL-1β and IL-23 values were higher in patients with sepsis and are potential diagnostic and prognostic markers for sepsis, but this needs to be confirmed by prospective studies.

Keywords: Diagnosis, IL23A Protein, Human, Interleukin 1beta (193-195), Prognosis, Sepsis


Sepsis is a life-threatening organ malfunction resulting from an abnormal host reaction to an infection [1], resulting in a high death rate among patients referred to the Intensive Care Unit (ICU) [2]. Globally, around 19–48.9 million people develop sepsis, among which nearly 11 million die [3]. According to a survey in China, the incidence of sepsis in the ICU was 20.6 for 100 ICU hospitalizations (95% confidence interval; CI=15.8–25.4), with a 90-day fatality rate of 35.5% [4]. Given the high morbidity and fatality of sepsis, diagnosing and managing sepsis poses a significant challenge in public health.

Due to a lack of a characteristic clinical presentation of sepsis, early prevention and treatment are difficult [5]. The single measurement of biomarkers has been extensively studied as a rapid and accurate method of infection diagnosis. Many novel biomarkers have been identified, such as CD5L [6], interleukin-26 (IL-26) [7], IL-17D [8], procalcitonin (PCT), and IL-10 [9], yet they have not been promoted and applied clinically due to low sensitivity and specificity. Hence, biomarkers with good diagnostic performance are crucial for early diagnosis, therapy, and prediction of sepsis.

IL-1β, a crucial pro-inflammatory cytokine, is involved in autoimmune inflammatory responses and multiple cellular activities, such as cell proliferation, differentiation, and apoptosis [10]. IL-1β dysregulation is associated with many pathological conditions, including sepsis [11], rheumatoid arthritis [12], and inflammatory bowel disease [13]. IL-23 is the central cytokine of autoimmunity and is an extremely promising therapeutic target for inflammatory diseases [14,15]. An imbalance in the IL-23/IL-17 axis is closely related to developing sepsis [16]. However, studies on the involvement of IL-1β and IL-23 in the development and progression of sepsis are still relatively scarce. Accordingly, we focused on assessing IL-1β and IL-23 for sepsis diagnosis and prediction.

Material and Methods


This retrospective, single-center investigation was conducted in a 2200-bed tertiary, comprehensive hospital in China. From January to December 2021, 74 individuals who fulfilled the clinical criteria for sepsis-3.0 [17] at Yiyang Central Hospital were enrolled as the sepsis group, consisting of 55 men and 19 women, with a median age of 56 years (inter-quartile range [IQR], 43–68). The control group consisted of 45 critically ill patients without sepsis but with critical illness (poly-trauma, cerebral trauma, or burns), who were hospitalized in the ICU, including 29 men and 16 women, with a median age of 61 years (IQR, 52.5–68). The healthy control group consisted of 50 healthy individuals from the Physical Examination Center of our hospital, including 29 males and 21 females, with a median age of 54.5 years (IQR 45.5–67). Septic patients were allocated into 2 groups based on 28-day survival: the survival group (n=43) included 33 males, and 10 females, with a median age of 53 years (IQR 43–70), and the non-survival group (n=31) consisted of 22 males and 9 females, with a median age of 56 years (IQR 44–66).

The exclusion criteria were: (1) age less than 18 years old; (2) pregnant, possibly pregnant, or lactating women; (3) patients with cancer, immunodeficiency disease, autoimmune disease, and using immunosuppressive medication in the past 8 weeks; (4) with acute cardiovascular and cerebrovascular disease; (5) missing key clinical information; and (6) refused to take part in the research. The Ethics Committee of Yiyang Central Hospital authorized this study (no. 2021-0065). Informed consent was waived as the study was retrospective.


Clinical data were obtained retrospectively from the hospital information system (HIS), including age, sex, underlying disease (urinary stones, cerebral vascular disease, diabetes mellitus, hypertension, hypoproteinemia), vital signs, length of hospital stay, and 28-day mortality. Within 24 h of admission, laboratory values were obtained retrospectively from the Laboratory Information System (LIS), including routine blood tests, creatinine (Cr; standard values: 44.0–136.0 μmol/L), blood urea nitrogen (BUN, standard values: 1.8–7.1 mmol/L), uric acid (UA; standard values: 150–420 μmol/L), total bilirubin (TBI; normal values: 5.1–19.0 μmol/L), lactate (standard values: 0.5–2.2 mmol), C-reactive protein (standard values: <10 mg/L), procalcitonin (standard values: <0.5 ng/mL), and SOFA (Sequential Organ Failure Assessment) scores.


Venous blood samples were collected at admission within 24 h and stored in a freezer at −80°C. Immunotag™ Human IL-23 ELISA was purchased from G-Biosciences (St. Louis, USA). IL-1β and IL-23 serum values were detected utilizing enzyme-linked immunosorbent assay (ELISA) kits.


The statistical analysis was carried out using SPSS v25.0. (IBM, Chicago, IL, USA). Figures 4 and 5 were generated using GraphPad Prism 9.0 (GraphPad, Inc., San Diego, CA). Risk Factor Analysis (Figure 2) and Cox Models Forest (Figure 3) were performed by using Data Analysis tools in Hiplot Pro (https://hiplot.com.cn/), a comprehensive web service for biomedical data analysis and visualization. For data with non-normal distribution, non-parametric methods were used for statistical analyses. Continuous variables were presented as medians (interquartile range) and 3 groups were compared using the Kruskal-Wallis test. Two groups were assessed utilizing the Mann-Whitney U test. The χ2 or Fisher’s exact test, as relevant, was employed to compare the frequencies (percentage) of categorical variables. To evaluate the diagnostic and prognostic usefulness of IL-1β and IL-23 in sepsis, the receiver operating characteristics (ROC) curve was utilized. SOFA score was employed to evaluate the degree of sepsis. Afterward, risk factor analysis was conducted to elucidate the association of IL-1β, IL-23, and procalcitonin (PCT) with SOFA score. Furthermore, univariate Cox regression analysis was conducted to assess the risk variables for sepsis fatality at 28 days. Finally, we performed survival analysis (SA) utilizing the Kaplan-Meier (K-M) technique and a log-rank test according to the cutoff value of IL-1β (9.41 pg/mL) and IL-23 (6.77 pg/mL). P values <0.05 were judged statistically significant.



Table 1 displays the basic demographics and laboratory data of participants. We enrolled 74 individuals with sepsis, 50 sex- and age-matched healthy controls, and 45 sex- and age-matched ICU controls. The 28-day mortality rate was 40.7% in the septic patients (n=31). Compared to healthy controls, the median levels of white blood cells (WBC), neutrophils, and monocytes were significantly higher in septic patients, whereas the median levels of lymphocytes, hematocrit, and platelets (PLT) were significantly lower in septic patients. Cr, BUN, total bilirubin (TBI), PCT, and SOFA ratings were all significantly higher in septic individuals contrasted with ICU controls (all P<0.05). IL-1β and IL-23 in the sera of 74 septic patients on the hospitalization day were significantly higher than those of ICU patients and healthy controls (P<0.05).


Figure 1 shows the ROC curves of IL-1β and IL-23 for diagnosing sepsis. When distinguishing between 74 septic patients and 45 non-sepsis patients (ICU controls), the AUC of IL-1β was 0.72 [P<0.001, 95% CI (0.64–0.80)], and the AUC of IL-23 was 0.80 [P<0.001, 95% CI (0.73–0.87)]. The ROC curves demonstrated that the diagnostic reliabilities of IL-1β and IL-23 were lower than the SOFA score [AUC=0.98, P<0.001, 95% CI (0.97–1.00)] but superior to PCT [AUC=0.71, P<0.001, 95% CI (0.61–0.80)].


Sepsis individuals were further stratified by 28-day mortality into survival and non-survival. Table 2 displays the distinct features of the survival and non-survival groups. There was no statistically significant difference between these indicators: age, sex, underlying disease, vital signs, and length of hospital stay (all P>0.05). There were no significant differences in these laboratory indicators: blood routine, Cr, BUN, UA, TBI, partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2), lactate, and C-reactive protein (CRP; all P>0.05). However, the median PCT, IL-1β, IL-23, and SOFA scores in the non-survival group were significantly higher than in the survival group. To elucidate the association of serum IL-1β and IL-23 levels with the severity of sepsis, we performed risk factor analysis, which showed that higher SOFA scores were associated with higher levels of IL-1β (r=0.480, P<0.001), IL-23 (r=0.476, P<0.001), and PCT (r=0.204, P=0.027) (Figure 2).


Univariate Cox regression analysis was conducted to assess the variables associated with 28-day mortality in septic individuals. PCT (hazard ratio; HR=1.02, P=0.001), IL-1β (HR=1.06, P<0.001), IL-23 (HR=1.02, P=0.031), and SOFA score (HR=1.15, P=0.004) were independent risk variables for 28-day mortality in septic individuals (Figure 3).

Furthermore, we constructed ROC curves to predict 28-day mortality by using serum IL-1β and IL-23 values (Figure 4). For the performance of variables in predicting 28-day mortality, the AUC of IL-23 was 0.77 [P<0.001, 95% CI (0.65–0.86)], with 87.10% sensitivity and 67.44% specificity, which was higher than PCT [AUC=0.67, P=0.008, 95% CI (0.55–0.77)] and IL-1β [AUC=0.66, P=0.024, 95% CI (0.54–0.76)], but lower than SOFA score [AUC=0.78, P<0.001, 95% CI (0.61–0.87)].

According to the threshold values of IL-1β (9.41 pg/mL) and IL-23 (6.77 pg/mL) for the estimated 28-day mortality of septic individuals, K-M survival curves were created (Figure 4). Patients with higher serum IL-1β (Figure 5A) and IL-23 (Figure 5B) concentrations had worse survival than patients with lower serum IL-1β and IL-23 concentrations.



Due to the limited experimental settings, this research has some flaws. First, because no fundamental experiments were undertaken, it is difficult to assess if the hypothesized mechanisms of action of IL-1β and IL-23 in sepsis agree with those proposed here. We hope that domestic and international investigators will perform trials to verify our claims. Second, our investigation was a single-center retrospective study with few participants, which may have resulted in selection bias and somewhat unreliable results. Consequently, the trial outcomes could be contingent. We shall perform a more thorough and in-depth prospective investigation to acquire the best possible trial findings. Third, an ICU control group was set up in this study, but non-septic patients with underlying diseases of poly-trauma, cerebral trauma, or burns were in critical condition when they were admitted, and required care and treatment in the ICU. We analyzed only the laboratory indicators within 24 h of admission in the ICU controls. The reliability of the results was further reduced by the delayed organismal stress response, which resulted in large differences between the ICU controls and septic patients. Fourth, there was no dynamic monitoring of serum IL-1β and IL-23 levels in patients with sepsis; therefore, it was difficult to assess the temporal correlation between the evolution of sepsis and their value. Overall, these results need to be further confirmed by additional studies.


Levels of IL-1β and IL-23 were significantly higher in patients. Early monitoring of IL-1β and IL-23 levels in individuals can be potential diagnostic and predictive biomarkers for sepsis since they are independent risk factors for predicting mortality within 28 days of sepsis. However, this needs to be confirmed by further prospective studies.


1. Fortini A, Faraone A, Meini S, Validity of “Sepsis-3” criteria in identifying patients with community-onset sepsis in Internal Medicine wards; A prospective, multicenter study: Eur J Intern Med, 2021; 85; 92-97

2. Qiu Z, Shen K, Shu MValue of Hepcidin as a diagnostic biomarker of sepsis in critically ill adults: Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, 2018; 30(7); 652-57 [in Chinese]

3. Chiu C, Legrand M, Epidemiology of sepsis and septic shock: Curr Opin Anaesthesiol, 2021; 34(2); 71-76

4. Xie J, Wang H, Kang Y, The epidemiology of sepsis in Chinese ICUs: A national cross-sectional survey: Crit Care Med, 2020; 48(3); e209-e18

5. Bracht H, Hafner S, Weiss MSepsis update: Definition and epidemiology: Anasthesiol Intensivmed Notfallmed Schmerzther, 2019; 54(1); 10-20 [in German]

6. Gao X, Liu Y, Xu F, Assessment of apoptosis inhibitor of macrophage/CD5L as a biomarker to predict mortality in the critically ill with sepsis: Chest, 2019; 156(4); 696-705

7. Tu H, Lai X, Li J, Interleukin-26 is overexpressed in human sepsis and contributes to inflammation, organ injury, and mortality in murine sepsis: Crit Care, 2019; 23(1); 290

8. Yan X, Tu H, Liu Y, Interleukin-17D aggravates sepsis by inhibiting macrophage phagocytosis: Crit Care Med, 2020; 48(1); e58-e65

9. Zhang W, Wang W, Hou W, The diagnostic utility of IL-10, IL-17, and PCT in patients with sepsis infection: Front Public Health, 2022; 10; 923457

10. Dinarello C, Arend W, Sims J, IL-1 family nomenclature: Nat Immunol, 2010; 11(11); 973

11. Kimura A, Kitajima M, Nishida K, NQO1 inhibits the TLR-dependent production of selective cytokines by promoting IkappaB-zeta degradation: J Exp Med, 2018; 215(8); 2197-209

12. Yang J, Wang J, Liang X, IL-1beta increases the expression of inflammatory factors in synovial fluid-derived fibroblast-like synoviocytes via activation of the NF-kappaB-mediated ERK-STAT1 signaling pathway: Mol Med Rep, 2019; 20(6); 4993-5001

13. Luong P, Hedl M, Yan J, INAVA-ARNO complexes bridge mucosal barrier function with inflammatory signaling: Elife, 2018; 7; e38539

14. Moschen AR, Tilg H, Raine T, IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting: Nat Rev Gastroenterol Hepatol, 2019; 16(3); 185-96

15. Bridgewood C, Newton D, Bragazzi N, Unexpected connections of the IL-23/IL-17 and IL-4/IL-13 cytokine axes in inflammatory arthritis and enthesitis: Semin Immunol, 2021; 58; 101520

16. Sun JK, Zhang WH, Chen WX, Effects of early enteral nutrition on Th17/Treg cells and IL-23/IL-17 in septic patients: World J Gastroenterol, 2019; 25(22); 2799-808

17. Singer M, Deutschman CS, Seymour CW, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3): JAMA, 2016; 315(8); 801-10

18. von Cube M, Schumacher M, Timsit JF, Sepsis: Lancet, 2020; 396(10265); 1804

19. Gaini S, Relster MM, Pedersen C, Johansen IS, Prediction of 28-days mortality with sequential organ failure assessment (SOFA), quick SOFA (qSOFA) and systemic inflammatory response syndrome (SIRS) – a retrospective study of medical patients with acute infectious disease: Int J Infect Dis, 2019; 78; 1-7

20. Pierrakos C, Velissaris D, Bisdorff M, Biomarkers of sepsis: Time for a reappraisal: Crit Care, 2020; 24(1); 287

21. Prescott HC, Angus DC, Enhancing recovery from sepsis: A review: JAMA, 2018; 319(1); 62-75

22. Gupta DL, Bhoi S, Mohan T, Coexistence of Th1/Th2 and Th17/Treg imbalances in patients with post traumatic sepsis: Cytokine, 2016; 88; 214-21

23. Deng P, Tang N, Li L, Diagnostic value of combined detection of IL-1beta, IL-6, and TNF-alpha for sepsis-induced cardiomyopathy: Med Clin (Barc), 2022; 158(9); 413-17

24. Evavold CL, Kagan JC, Inflammasomes: Threat-assessment organelles of the innate immune system: Immunity, 2019; 51(4); 609-24

25. Liu X, Nemeth DP, McKim DB, Cell-type-specific interleukin 1 receptor 1 signaling in the brain regulates distinct neuroimmune activities: Immunity, 2019; 50(2); 317-33e316

26. Xiong S, Hong Z, Huang LS, IL-1beta suppression of VE-cadherin transcription underlies sepsis-induced inflammatory lung injury: J Clin Invest, 2020; 130(7); 3684-98

27. Frieder J, Kivelevitch D, Haugh I, Anti-IL-23 and anti-IL-17 biologic agents for the treatment of immune-mediated inflammatory conditions: Clin Pharmacol Ther, 2018; 103(1); 88-101

In Press

31 May 2023 : Review article  

Prevalence, Diagnosis, and Management of Eclampsia and the Need for Improved Maternal Care: A Review

Med Sci Monit In Press; DOI: 10.12659/MSM.939919  

30 May 2023 : Clinical Research  

A Case-Control Study of Cognitive Function in Patients with End-Stage Renal Disease Before and After Hemodi...

Med Sci Monit In Press; DOI: 10.12659/MSM.940409  

30 May 2023 : Review article  

A Review of the Role of the Zebrafish (Danio reiro) in Preclinical and Clinical Models of Biomarker Identif...

Med Sci Monit In Press; DOI: 10.12659/MSM.940550  

30 May 2023 : Database Analysis  

The COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in Poland

Med Sci Monit In Press; DOI: 10.12659/MSM.940904  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788


30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750